Sheep anti-Alpha-synuclein Polyclonal Antibody (Unconjugated), suitable for IHC-Frozen, IHC-Paraffin-embedded.
Background Info:
Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.
Product Type:
Antibody
Antibody Type:
Polyclonal
Format:
Lyophilized
Host Animal:
Sheep
Species Reactivity:
Human,Rat
Immunogen:
A synthetic peptide (PQEGILEDMPVDPC) of human alpha synuclein protein (aa: 108-120) conjugated to diphtheria toxoid has been used as the immunogen.
Applications:
IHC-Frozen,IHC-Paraffin-embedded
Antibody Isotype:
IgG
Application Details:
IHC. Recommended to be used at a concentration of 1 µg/mL for immunohistochemistry (Paraffin sections). Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Alternative Names:
Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
References:
Lundvig, et al http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15790525'>Brain Res Mol Brain Res 134, 3-17 (Mar 24, 2005). Bennett, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15737408'>Pharmacol Ther 105, 311-31 (Mar, 2005). Vekrellis, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15247485'>Mol Neurobiol 30, 1-21 (Aug, 2004). Martin, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15182224'>Protein Pept Lett 11, 229-37 (Jun, 2004). Doherty, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14648076'>Acta Neuropathol (Berl) 107, 169-75 (Feb, 2004). Goedert, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11377973'>Curr Opin Genet Dev 11, 343-51 (Jun, 2001). Saito, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10967182'>J Neurol Sci 177, 48-59 (Aug 1, 2000). Lucking et al. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11215516'>Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908. Kahle, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11193173'>Ann N Y Acad Sci 920, 33-41 (2000). Clayton, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9641537'>Trends Neurosci 21, 249-54 (Jun, 1998).
Specificity:
Immunihistochemical analysis of human and rat brain indicates a high level of specificity for this antiserum. Specificity was also confirmed by western blot. This antiserum is known to react with human and rat alpha synuclein.
Purification:
Affinity purified and dialysed against PBS. Contains 0.02% sodium azide.
Target:
Alpha-synuclein
Accession Number:
P37840
Research Areas:
Antibodies & Conjugates/Biosensis Alzheimer's & Parkinson's/sheep antibody to alpha synuclein
Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.
Product Type:
Antibody
Antibody Type:
Polyclonal
Format:
Lyophilized
Host Animal:
Sheep
Species Reactivity:
Human,Mouse,Rat
Immunogen:
A synthetic peptide (CMPVDPDNEAYEMPSEE) of human alpha synuclein protein (aa: 116-131) conjugated to diphtheria toxoid has been used as the immunogen.
Applications:
ELISA,IHC-Frozen,IHC-Paraffin-embedded,WB
Antibody Isotype:
IgG
Application Details:
Immunohistochemistry (IHC): 1-4 µg/mL (paraffin sections) Western Blotting (WB): 0.5 - 2.0 µg/mL. Fixing of proteins on membrane with 0.4% formaldehyde (30 min at room temperature) recommended, see Lee & Kamitani, 2011. Flow Cytometry: 2 µg antibody per ~10^6 cells, methanol-fixed. Immunocytochemistry (ICC): 1-4 µg/mL, 4% formaldehyde-fixed cells. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Alternative Names:
Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
References:
Lundvig et al, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15790525'>Brain Res Mol Brain Res 134, 3-17 (Mar 24, 2005). Bennett, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15737408'>Pharmacol Ther 105, 311-31 (Mar, 2005). Vekrellis, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15247485'>Mol Neurobiol 30, 1-21 (Aug, 2004). Martin, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15182224'>Protein Pept Lett 11, 229-37 (Jun, 2004). Doherty, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14648076'>Acta Neuropathol (Berl) 107, 169-75 (Feb, 2004). Goedert, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11377973'>Curr Opin Genet Dev 11, 343-51 (Jun, 2001). Saito, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10967182'>J Neurol Sci 177, 48-59 (Aug 1, 2000). Luecking C.B. et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids= 11215516'>Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908. Kahle, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11193173'>Ann N Y Acad Sci 920, 33-41 (2000). Clayton, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9641537'>Trends Neurosci 21, 249-54 (Jun, 1998).
Specificity:
This antiserum specifically detects alpha synuclein. This antibody is known to react with alpha synuclein of human, mouse, rat and other rodents.
Purification:
Affinity purified and dialysed against phosphate buffered saline (PBS).
Target:
Alpha-synuclein
Accession Number:
P37840
Research Areas:
Antibodies & Conjugates/Biosensis Alzheimer's & Parkinson's/sheep antibody to alpha synuclein
Sheep anti-Pan-synuclein Polyclonal Antibody (Unconjugated), suitable for WB, IHC-Frozen.
Background Info:
Detects human alpha-, beta-, and gamma synuclein proteins. A family of homologous proteins known as alpha-, beta-, and gamma-synuclein are abundantly expressed in brain, especially in the presynaptic terminal of neurons. Although the precise function of these proteins remains unknown, alpha-synuclein has been implicated in synaptic plasticity associated with avian song learning as well as in the pathogenesis of Parkinson's disease (PD), dementia with LBs (DLB), some forms of Alzheimer's disease (AD), and multiple system atrophy (MSA).
Product Type:
Antibody
Antibody Type:
Polyclonal
Format:
Lyophilized
Host Animal:
Sheep
Species Reactivity:
Human,Rat
Immunogen:
A synthetic peptide (AKEGVVAAAEKTKQGV) as a consensus part of human alpha-, beta-, and gamma synuclein proteins conjugated to diphteria toxoid has been used as the immunogen.
Applications:
IHC-Frozen,WB
Antibody Isotype:
IgG
Application Details:
IHC, WB. A concentration of 3 µg/mL is recommended for immunohistochemistry (frozen & paraffin embedded sections) and 1 µg/mL for western blot. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
References:
Lundvig, et al http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15790525'>Brain Res Mol Brain Res 134, 3-17 (Mar 24, 2005). Bennett, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15737408'>Pharmacol Ther 105, 311-31 (Mar, 2005). Vekrellis, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15247485'>Mol Neurobiol 30, 1-21 (Aug, 2004). Martin, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15182224'>Protein Pept Lett 11, 229-37 (Jun, 2004). Doherty, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14648076'>Acta Neuropathol (Berl) 107, 169-75 (Feb, 2004). Goedert, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11377973'>Curr Opin Genet Dev 11, 343-51 (Jun, 2001). Saito, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10967182'>J Neurol Sci 177, 48-59 (Aug 1, 2000). Lucking et al. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11215516'>Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908. Kahle, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11193173'>Ann N Y Acad Sci 920, 33-41 (2000). Clayton, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9641537'>Trends Neurosci 21, 249-54 (Jun, 1998).
Specificity:
Overlap specific immunohistochemical staining of alpha-, beta- and gamma synucleins This antiserum recognises human and rat alpha-, beta- and gamma synucleins.
Purification:
Affinity purified and dialysed against PBS. Contains 0.02% sodium azide.
Target:
Pan-synuclein
Accession Number:
P37840; Q16143; O76070
Research Areas:
Antibodies & Conjugates/Biosensis Alzheimer's & Parkinson's/sheep antibody to alpha synuclein
Sheep anti-Alpha-synuclein Polyclonal Antibody (Unconjugated), suitable for IHC-Frozen.
Background Info:
Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.
Product Type:
Antibody
Antibody Type:
Polyclonal
Format:
Lyophilized
Host Animal:
Sheep
Species Reactivity:
Human,Mouse,Rat
Immunogen:
A synthetic peptide (CMPVDPDNEAYEMPSEE) as part of human alpha synuclein (aa: 116-131) conjugated to KLH has been used as the immunogen.
Applications:
IHC-Frozen
Antibody Isotype:
Mixed
Application Details:
IHC with 1:1000 to 1:2000 dilution. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Alternative Names:
Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
References:
Lundvig, et al http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15790525'>Brain Res Mol Brain Res 134, 3-17 (Mar 24, 2005). Bennett, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15737408'>Pharmacol Ther 105, 311-31 (Mar, 2005). Vekrellis, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15247485'>Mol Neurobiol 30, 1-21 (Aug, 2004). Martin, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15182224'>Protein Pept Lett 11, 229-37 (Jun, 2004). Doherty, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14648076'>Acta Neuropathol (Berl) 107, 169-75 (Feb, 2004). Goedert, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11377973'>Curr Opin Genet Dev 11, 343-51 (Jun, 2001). Saito, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10967182'>J Neurol Sci 177, 48-59 (Aug 1, 2000). Luecking C.B. et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids= 11215516'>Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908. Kahle, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11193173'>Ann N Y Acad Sci 920, 33-41 (2000). Clayton, et al., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9641537'>Trends Neurosci 21, 249-54 (Jun, 1998).
Specificity:
Immunohistochemistry shows a high specificity for alpha-synuclein. This antibody is known to react with human, rat and mouse alpha-synuclein.
Purification:
Whole serum
Target:
Alpha-synuclein
Accession Number:
P37840
Research Areas:
Antibodies & Conjugates/Biosensis Alzheimer's & Parkinson's/sheep antibody to alpha synuclein
Cookies:
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
